Found: 37
Select item for more details and to access through your institution.
Clinical Images: Subacute panniculitis‐like T cell lymphoma in systemic lupus erythematosus.
- Published in:
- ACR Open Rheumatology, 2024, v. 6, n. 1, p. 4, doi. 10.1002/acr2.11615
- By:
- Publication type:
- Article
T-Cell Prolymphocytic Leukemia with Extensive Cardiovascular Infiltrate Leading to Multiple Myocardial Infarctions and Cardiac Death.
- Published in:
- Texas Heart Institute Journal, 2014, v. 41, n. 6, p. 626, doi. 10.14503/THIJ-13-3581
- By:
- Publication type:
- Article
Peripheral T cell lymphoma, not otherwise specified (PTCL‐NOS). A new prognostic model developed by the International T cell Project Network.
- Published in:
- British Journal of Haematology, 2018, v. 181, n. 6, p. 760, doi. 10.1111/bjh.15258
- By:
- Publication type:
- Article
Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis.
- Published in:
- British Journal of Haematology, 2015, v. 170, n. 4, p. 504, doi. 10.1111/bjh.13463
- By:
- Publication type:
- Article
Addition of lenalidomide to rituximab, ifosfamide, carboplatin, etoposide ( RICER) in first-relapse/primary refractory diffuse large B-cell lymphoma.
- Published in:
- British Journal of Haematology, 2014, v. 166, n. 1, p. 77, doi. 10.1111/bjh.12846
- By:
- Publication type:
- Article
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR™ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.
- Published in:
- Investigational New Drugs, 2014, v. 32, n. 6, p. 1213, doi. 10.1007/s10637-014-0125-2
- By:
- Publication type:
- Article
Improved Survival of Lymphoma Patients with COVID-19 in the Modern Treatment and Vaccination Era.
- Published in:
- Cancers, 2022, v. 14, n. 17, p. 4252, doi. 10.3390/cancers14174252
- By:
- Publication type:
- Article
Reversible Photochromic Reactions of Bacteriorhodopsin from Halobacterium salinarum at Femto- and Picosecond Times.
- Published in:
- Molecules, 2024, v. 29, n. 20, p. 4847, doi. 10.3390/molecules29204847
- By:
- Publication type:
- Article
Prevalence of non-Hodgkin lymphoma patients at high-risk of failure after CAR T-cell therapy eligible for bridging radiation therapy.
- Published in:
- Frontiers in Oncology, 2024, p. 1, doi. 10.3389/fonc.2024.1425506
- By:
- Publication type:
- Article
Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2024, v. 24, n. 8, p. 523, doi. 10.1016/j.clml.2024.03.011
- By:
- Publication type:
- Article
Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 7, p. e435, doi. 10.1016/j.clml.2021.12.012
- By:
- Publication type:
- Article
TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S411, doi. 10.1016/S2152-2650(21)01925-X
- By:
- Publication type:
- Article
HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S371, doi. 10.1016/S2152-2650(21)01849-8
- By:
- Publication type:
- Article
Poster: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S247, doi. 10.1016/S2152-2650(21)01557-3
- By:
- Publication type:
- Article
Poster: HL-147: Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S236, doi. 10.1016/S2152-2650(21)01485-3
- By:
- Publication type:
- Article
Oral Abstract: TCL-150: The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S203, doi. 10.1016/S2152-2650(21)01276-3
- By:
- Publication type:
- Article
Treatment of Peripheral T-Cell Lymphoma in Community Settings.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Cost-effectiveness of Brentuximab Vedotin With Chemotherapy in Treatment of CD30-Expressing PTCL.
- Published in:
- American Journal of Managed Care, 2020, v. 26, n. 2, p. e41, doi. 10.37765/ajmc.2020.42400
- By:
- Publication type:
- Article
Subcutaneous Epcoritamab in Patients With Relapsed or Refractory Large B-Cell Lymphoma (EPCORE NHL-1): Pivotal Results From a Phase 2 Study.
- Published in:
- Acta Haematologica Polonica, 2022, v. 53, n. A, p. 44
- By:
- Publication type:
- Article
Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.
- Published in:
- Blood Cancer Journal, 2019, v. 9, n. 6, p. N.PAG, doi. 10.1038/s41408-019-0208-6
- By:
- Publication type:
- Article
Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 9, p. 894, doi. 10.1002/ajh.24429
- By:
- Publication type:
- Article
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: Characteristics, outcomes, and prognostication among a large multicenter cohort.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 9, p. 778, doi. 10.1002/ajh.24082
- By:
- Publication type:
- Article
Reduced-dose fludarabine, cyclophosphamide, and rituximab (FCR-Lite) plus lenalidomide, followed by lenalidomide consolidation/maintenance, in previously untreated chronic lymphocytic leukemia.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 6, p. 487, doi. 10.1002/ajh.23983
- By:
- Publication type:
- Article
Anti-spike antibody response to the COVID vaccine in lymphoma patients.
- Published in:
- PLoS ONE, 2022, v. 17, n. 12, p. 1, doi. 10.1371/journal.pone.0266584
- By:
- Publication type:
- Article
The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.
- Published in:
- 2019
- By:
- Publication type:
- journal article
A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 14, p. 3565, doi. 10.1002/cncr.26731
- By:
- Publication type:
- Article
Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD courses.
- Published in:
- British Journal of Haematology, 2011, v. 152, n. 5, p. 551, doi. 10.1111/j.1365-2141.2010.08485.x
- By:
- Publication type:
- Article
Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
- Published in:
- British Journal of Haematology, 2010, v. 151, n. 1, p. 47, doi. 10.1111/j.1365-2141.2010.08315.x
- By:
- Publication type:
- Article
Outcomes and Toxicities of Programmed Death‐1 (PD‐1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real‐World, Multicenter Retrospective Analysis.
- Published in:
- Oncologist, 2019, v. 24, n. 7, p. 955, doi. 10.1634/theoncologist.2018-0538
- By:
- Publication type:
- Article
Proteasome Inhibition and Combination Therapy for Non-Hodgkin's Lymphoma: From Bench to Bedside.
- Published in:
- Oncologist, 2012, v. 17, n. 5, p. 694, doi. 10.1634/theoncologist.2011-0341
- By:
- Publication type:
- Article
Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.
- Published in:
- Acta Haematologica, 2020, v. 143, n. 1, p. 40, doi. 10.1159/000500666
- By:
- Publication type:
- Article
Kaposi Sarcoma-Associated Herpesvirus (Human Herpesvirus Type 8)-Associated Extracavitary Lymphoma: Report of a Case in an HIV-Positive Patient with Simultaneous Kaposi Sarcoma and a Review of the Literature.
- Published in:
- Acta Haematologica, 2010, v. 123, n. 4, p. 237, doi. 10.1159/000314347
- By:
- Publication type:
- Article
Patients With Natural Killer (NK) Cell Chronic Active Epstein-Barr Virus Have Immature NK Cells and Hyperactivation of PI3K/Akt/mTOR and STAT1 Pathways.
- Published in:
- 2020
- By:
- Publication type:
- journal article